Neuroprotective Effects of the Glucagon-Like Peptide-1 Analog Exenatide After Out-of-Hospital Cardiac Arrest
Authors
Discussion
Loading...
Member takes
Implication
Randomized trial investigates neuroprotective effects of exenatide in comatose OHCA patients, suggesting safety but no significant efficacy.
Key Points
- This trial aimed to investigate the neuroprotective effects of exenatide in patients resuscitated from out-of-hospital cardiac arrest (OHCA).
- Randomly assigned 120 comatose patients resuscitated from OHCA in a double-blind, 2-center trial.
- Administered 17.4 μg exenatide or placebo over a 6-hour and 15-minute infusion.
- Coprimary endpoints included feasibility of drug initiation and efficacy based on neuron-specific enolase levels.
- Study drug was initiated in 96% of patients within 240 minutes of return of spontaneous circulation.
- Exenatide resulted in lower median blood glucose (5.8 mmol/L) compared to placebo (7.3 mmol/L, P<0.0001).
- No significant differences in neuron-specific enolase levels or composite endpoints of death and poor neurological function were found.
Cite This Study
Wiberg et al. (2016) studied this question.